LL-37: Evaluating the Therapeutic Potential and Regulatory Landscape of the Sole Human Cathelicidin

This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

1. Clinical Question

How do the endogenous antimicrobial and immunomodulatory activities of LL-37 relate to its current evidence base and regulatory status as an exogenous therapeutic agent?

2. Evidence Snapshot

• Peptide Classification: Endogenous 37-amino acid human cathelicidin (the only cathelicidin present in humans).
• Evidence Grade: C.
• Evidence Type: Well-studied as an endogenous peptide; no clinical trial data for exogenous administration.
• Antimicrobial Profile: Broad-spectrum activity against bacteria, viruses, and fungi.
• FAERS Safety Signals: None reported.
• Regulatory Status: Not FDA-approved as a therapeutic; listed as Category 2 (September 2023) due to safety concerns.

3. What the Research Shows

LL-37 is characterized as the only member of the cathelicidin family of antimicrobial peptides found in humans. Research currently establishes LL-37 as an endogenous 37-amino acid peptide that is well-studied in its naturally occurring state. However, the transition from endogenous observation to exogenous therapeutic application is not supported by clinical data.

There are currently zero clinical trials listed for the exogenous administration of LL-37. Consequently, while the peptide is identified for its broad-spectrum activity against various pathogens, there are no human outcomes or clinical data points to confirm its efficacy or safety when administered as a drug.

Regulatory assessments have noted concerns regarding the peptide. As of September 2023, LL-37 is categorized as Category 2, a designation involving safety concerns. Furthermore, the peptide was mentioned in a 2020 FDA warning letter issued to Tailor Made Compounding.

4. Mechanism

Based on available mechanistic data, LL-37 functions as a pleiotropic molecule. Its primary mechanism involves broad-spectrum antimicrobial activity effective against bacteria, fungi, and viruses. Beyond direct antimicrobial action, it modulates immune responses through the regulation of Toll-like receptor (TLR) signaling. Additionally, LL-37 has been shown to promote wound healing processes specifically by inducing keratinocyte migration.

5. Limitations of the Evidence

The primary limitation of LL-37 evidence is the significant gap between endogenous knowledge and therapeutic evidence. While the endogenous peptide is well-studied, exogenous therapeutic administration lacks any clinical trial data.

From a pharmaceutical perspective, LL-37 faces substantial hurdles. Stability and delivery mechanisms remain significant challenges that have not been resolved in the current literature. Furthermore, the FDA has identified safety concerns leading to its Category 2 status. There is a total absence of FAERS safety signal data, which may be due to the lack of formal clinical utilization and monitoring.

6. Clinical Takeaway

LL-37 is a unique endogenous cathelicidin with a robust mechanistic profile involving antimicrobial activity and wound healing through keratinocyte migration. However, the evidence for its use as a therapeutic agent is limited by a lack of clinical trials and Grade C evidence. Clinicians should note its current regulatory status as a Category 2 substance with noted safety concerns and the absence of FDA approval for any indication.

7. Sources

• TruthTides Clinical Database: LL-37 Peptide Profile [Grade: C].
• TruthTides Regulatory Status Record: 1a05a97a-57de-4769-92dd-2c32bdd5ecd3 (March 2026).